Company Overview and News


Add ADAP
to your dashboard

Headline News

Valeant (VRX) Earnings and Revenues Beat in Q3, Stock Up

2017-11-09 zacks
Shares of Valeant Pharmaceuticals Inc. (VRX - Free Report) rallied 23.6% after the company reported better-than-expected third-quarter results on Nov 7. (78-0)

Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3

2017-11-09 zacks
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) reported a loss of 5 cents per share in the third quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 6 cents. However, the figure was in line with the loss recorded in the year-ago quarter. (132-0)

Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up

2017-11-09 zacks
Merrimack Pharmaceuticals, Inc. (MACK - Free Report) reported a loss of 40 cents per share in the third quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of $1.88. The company had reported a loss of $2.06 in the year-ago quarter. (90-0)

Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates

2017-11-09 zacks
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) reported third-quarter 2017 earnings of 11 cents per share (including the impact of stock-based compensation) comparing favorably with the Zacks Consensus Estimate of a loss of 4 cents. However, earnings were lower than 20 cents recorded a year ago. (83-0)

Mallinckrodt (MNK) Earnings, Sales Decline Y/Y in Q3

2017-11-08 zacks
The company reported adjusted earnings of $1.97 per share in the reported quarter, down from the year-ago figure of $2.04 due to continued pricing pressure within the Specialty Generics. (66-0)

Keryx (KERX) Q3 Loss Wider Than Expected, Stock Declines

2017-11-08 zacks
Shares of Keryx Biopharmaceuticals Inc. (KERX - Free Report) were down almost 17% on Nov 7 despite receiving FDA approval for a label expansion of its lead drug Auryxia. Lower-than-expected sales of Auryxia in the third quarter led to the selloff. (88-0)

Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag

2017-11-08 zacks
Agenus Inc. (AGEN - Free Report) incurred loss of 37 cents per share in line with the Zacks Consensus Estimate. The figure came in narrower the year-ago loss of 47 cents. (109-0)

Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss

2017-11-07 zacks
Endocyte, Inc. (ECYT - Free Report) incurred a loss of 27 cents per share in third-quarter 2017 narrower than the Zacks Consensus Estimate of a loss of 35 cents. However, the figure came in wider than the year-ago loss of 21 cents. The loss has been adjusted to exclude an upfront payment of $12 million to ABX GmbH. (106-0)

What's in Store for Johnson Controls (JCI) in Q4 Earnings?

2017-11-07 zacks
Johnson Controls International plc (JCI - Free Report) is set to report fourth-quarter and full-year 2017 results on Nov 9, before market open. Last quarter, the company reported in-line results. In fact, the company beat earnings estimates in two of the trailing four quarters, with an average positive surprise of 5.14%. The long-term earnings per share growth (three-five years) for the company is currently pegged at 13. (58-0)

Adaptimmune Therapeutics' (ADAP) CEO James Noble on Q3 2017 Results - Earnings Call Transcript

2017-11-04 seekingalpha
Good day and welcome to the Q3 2017 Adaptimmune Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Juli Miller. Please go ahead, ma'am. (36-1)

AMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 Outlook

2017-11-04 zacks
AMAG Pharmaceuticals, Inc. (AMAG - Free Report) posted adjusted earnings of $1.57 per share in the third quarter of 2017 compared with 47 cents in the year-ago quarter. The reported earnings compared favorably with the Zacks Consensus Estimate of a loss of 4 cents. Notably, the figure included the income tax benefit gained in the quarter. (89-0)

Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3

2017-11-02 zacks
Epizyme, Inc. (EPZM - Free Report) reported a loss of 63 cents per share in the third quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 65 cents but wider than the year-ago loss of 42 cents. (79-2)

Novo Nordisk (NVO) Tops Q3 Earnings Estimates, Lags Sales

2017-11-01 zacks
Novo Nordisk A/S (NVO - Free Report) reported third-quarter 2017 earnings of 63 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 58 cents. In fact, the reported figure was ahead of 57 cents earned a year ago. (78-0)

Dr. Reddy's (RDY) Q2 Earnings and Revenues Decline Y/Y

2017-11-01 zacks
Dr. Reddy's Laboratories Ltd. (RDY - Free Report) reported second-quarter fiscal 2018 earnings per American Depositary Share (ADS) of 26 cents, down from 27 cents in the year-ago quarter. However, revenues decreased 1.1% year over year to $543 million. (80-0)

Alkermes (ALKS) Beats Q3 Earnings Estimates, Cuts Sales View

2017-10-27 zacks
Alkermes plc (ALKS - Free Report) reported earnings of 3 cents per share in the third quarter of 2017, beating the Zacks Consensus Estimate of a penny. The bottom line also bettered the loss of 9 cents incurred in the year-ago quarter. (100-0)

CUSIP: 00653A107